These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 9009470

  • 1. The pharmacology of ergotamine and dihydroergotamine.
    Silberstein SD.
    Headache; 1997; 37 Suppl 1():S15-25. PubMed ID: 9009470
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Migraine: dihydroergotamine nasal spray--an alternative].
    Beubler E.
    Wien Med Wochenschr; 1995; 145(14):326-31. PubMed ID: 7483646
    [Abstract] [Full Text] [Related]

  • 12. The antimigraine drugs ergotamine and dihydroergotamine are potent 5-HT1C receptor agonists in piglet choroid plexus.
    Brown AM, Patch TL, Kaumann AJ.
    Br J Pharmacol; 1991 Sep; 104(1):45-8. PubMed ID: 1786517
    [Abstract] [Full Text] [Related]

  • 13. Studies on the 5-HT receptor in vascular smooth muscle.
    Müller-Schweinitzer E.
    Res Clin Stud Headache; 1978 Sep; 6():6-12. PubMed ID: 725257
    [Abstract] [Full Text] [Related]

  • 14. Ergot pharmacology and alternative delivery systems for ergotamine derivatives.
    Goldstein J.
    Neurology; 1992 Mar; 42(3 Suppl 2):45-6. PubMed ID: 1557192
    [Abstract] [Full Text] [Related]

  • 15. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy.
    Villalón CM, Centurión D, Valdivia LF, De Vries P, Saxena PR.
    Proc West Pharmacol Soc; 2002 Mar; 45():199-210. PubMed ID: 12434581
    [Abstract] [Full Text] [Related]

  • 16. [Experimental pharmacological studies of the venous tonus-modifying effect of dihydroergotamine].
    Glusa E.
    Z Gesamte Inn Med; 1984 Sep 01; 39(17):414-7. PubMed ID: 6095548
    [Abstract] [Full Text] [Related]

  • 17. Ergotamine and dihydroergotamine enhance guanylate cyclase activity.
    Vesely DL.
    Res Commun Chem Pathol Pharmacol; 1983 May 01; 40(2):245-54. PubMed ID: 6136069
    [Abstract] [Full Text] [Related]

  • 18. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward.
    Tfelt-Hansen PC, Koehler PJ.
    Cephalalgia; 2008 Aug 01; 28(8):877-86. PubMed ID: 18460007
    [Abstract] [Full Text] [Related]

  • 19. Orally inhaled dihydroergotamine: a review.
    Tepper SJ.
    Headache; 2013 Sep 01; 53 Suppl 2():43-53. PubMed ID: 24024602
    [Abstract] [Full Text] [Related]

  • 20. The 5-HT1B and 5-HT1D agonists in acute migraine therapy: Ergotamine, dihydroergotamine, and the triptans.
    Whealy M, Becker WJ.
    Handb Clin Neurol; 2024 Sep 01; 199():17-42. PubMed ID: 38307644
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.